Comparing SHL Telemedicine (NASDAQ:SHLT) & Pono Capital Two (NASDAQ:PTWO)

Pono Capital Two (NASDAQ:PTWO) and SHL Telemedicine (NASDAQ:SHLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Pono Capital Two and SHL Telemedicine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pono Capital Two	0	0	0	0	N/A
SHL Telemedicine	0	0	1	0	3.00

SHL Telemedicine has a consensus price target of $11.00, suggesting a potential upside of 106.77%. Given SHL Telemedicine’s higher possible upside, analysts plainly believe SHL Telemedicine is more favorable than Pono Capital Two.

Valuation and Earnings

This table compares Pono Capital Two and SHL Telemedicine’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pono Capital Two	N/A	N/A	$340,000.00	N/A	N/A
SHL Telemedicine	$59.00 million	1.32	-$80,000.00	N/A	N/A

Pono Capital Two has higher earnings, but lower revenue than SHL Telemedicine.

Profitability

This table compares Pono Capital Two and SHL Telemedicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pono Capital Two	N/A	-6.63%	0.73%
SHL Telemedicine	N/A	N/A	N/A

Insider and Institutional Ownership

60.8% of Pono Capital Two shares are held by institutional investors. Comparatively, 20.1% of SHL Telemedicine shares are held by institutional investors. 63.9% of Pono Capital Two shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About Pono Capital Two

Pono Capital Two, Inc. does not have any significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2022 and is based in Honolulu, Hawaii.

About SHL Telemedicine

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. It offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. The company serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was founded in 1987 and is headquartered in Tel Aviv, Israel.